NASDAQ:PLUR

Pluri Q1 2027 Earnings Results & Report

Pluri logo
$0.95 +0.03 (+3.49%)
As of 02:44 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Pluri reported Q1 2027 earnings on November 12, 2026. The company reported EPS of -$0.85, while revenue was $759 thousand.

Earnings Announcement Details

Quarter
Q1 2027
Time
After Market Closes

Pluri EPS Results

Actual EPS
-$0.85
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 4 quarters

Pluri Revenue Results

Actual Revenue
$759 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Pluri Q1 2027 Earnings FAQ

Pluri (NASDAQ:PLUR) reported earnings of -$0.85 per share for Q1 2027. The report was announced on Thursday, November 12, 2026.

Pluri reported revenue of $759 thousand for Q1 2027.

Pluri Earnings Headlines

Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
See More Pluri Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pluri? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pluri and other key companies, straight to your email.

About Pluri

Pluri (NASDAQ:PLUR) Ltd. is an Israel-based biotechnology company developing cell-based products and technologies. Its therapeutic research centers on PLX cells, derived from human placental tissue and expanded using the company’s cell-manufacturing platform. Pluri has investigated these cells for potential use in a range of medical conditions; its therapies remain in development.

The company also applies its cell-expansion technology to areas beyond medicine, including food technology and agriculture, where it is exploring cell-based products and production methods.

Pluri was formerly known as Pluristem Therapeutics and adopted its current name in 2022 to reflect its broader focus on cell-based technologies. The company is headquartered in Haifa, Israel.

View Pluri Profile